middle.news
Mayne Pharma Doubles EBITDA in FY25, Launches New Dermatology Products
9:52am on Thursday 29th of January, 2026 AEDT
•
Pharmaceuticals
Read Story
Mayne Pharma Doubles EBITDA in FY25, Launches New Dermatology Products
9:52am on Thursday 29th of January, 2026 AEDT
Key Points
105% increase in underlying EBITDA to $47 million in FY25
Revenue growth to $408.1 million, up 5% from FY24
Launch of TWYNEO® and EPSOLAY® dermatology products in Q1 FY26
1H FY26 shows resilient earnings with margin improvements despite slight revenue dip
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
MAYNE PHARMA (ASX:MYX)
OPEN ARTICLE